Ticker LaunchIPO · HLVX
HilleVax, Inc.
HilleVax, Inc. (HLVX) priced its initial public offering on Apr 29, 2022 at $17.00 per share, within its $16.00–$18.00 range, raising $200M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $538.3M. J.P. Morgan was lead-left underwriter, joined by SVB, Stifel and Guggenheim. Latham & Watkins advised the company and Davis Polk advised the underwriters.
- Status
- IPO
- Ticker
- HLVX
- Exchange
- Nasdaq Global Select
- Priced
- Apr 29, 2022
- IPO price
- $17.00
- Price range
- $16.00–$18.00
- Raised
- $200M
- Market cap at IPO price
- $538.3M
- First filed
- Apr 6, 2022
- Underwriters
- J.P. Morgan, SVB, Stifel and Guggenheim
- Company counsel
- Latham & Watkins
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 6, 2022
- Latest amendment Apr 25, 2022
- Final prospectus (424B4) Apr 29, 2022
- All filings on EDGAR CIK 1888012
Other Biotech & pharma IPOs in 2022
- OKYO Pharma LtdOKYO · May 18, 2022 · $2.5M
- PepGen Inc.PEPG · May 9, 2022 · $108M
- Belite Bio, IncBLTE · Apr 29, 2022 · $36M
- AN2 Therapeutics, Inc.ANTX · Mar 28, 2022 · $69M
- Akanda Corp.AKAN · Mar 16, 2022
- Onconetix, Inc.BWV · Feb 23, 2022 · $20M